Veritas Investment Management LLP purchased a new stake in Illumina, Inc. (NASDAQ:ILMN) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 730 shares of the life sciences company’s stock, valued at approximately $222,000.
Other large investors also recently added to or reduced their stakes in the company. Bath Savings Trust Co boosted its holdings in Illumina by 42.6% during the second quarter. Bath Savings Trust Co now owns 1,062 shares of the life sciences company’s stock worth $391,000 after buying an additional 317 shares during the last quarter. Winfield Associates Inc. boosted its holdings in Illumina by 20.3% during the second quarter. Winfield Associates Inc. now owns 1,865 shares of the life sciences company’s stock worth $687,000 after buying an additional 315 shares during the last quarter. KAMES CAPITAL plc boosted its holdings in Illumina by 58.8% during the second quarter. KAMES CAPITAL plc now owns 162,766 shares of the life sciences company’s stock worth $59,922,000 after buying an additional 60,287 shares during the last quarter. Copper Rock Capital Partners LLC bought a new position in shares of Illumina during the 2nd quarter valued at about $10,888,000. Finally, Zions Bancorporation N.A. lifted its holdings in shares of Illumina by 4.9% during the 2nd quarter. Zions Bancorporation N.A. now owns 1,313 shares of the life sciences company’s stock valued at $483,000 after purchasing an additional 61 shares in the last quarter. Institutional investors and hedge funds own 90.94% of the company’s stock.
Shares of NASDAQ:ILMN traded up $1.61 during trading on Monday, hitting $295.00. 743,530 shares of the company were exchanged, compared to its average volume of 1,039,040. The stock has a market cap of $44.23 billion, a price-to-earnings ratio of 51.57, a P/E/G ratio of 2.22 and a beta of 1.03. Illumina, Inc. has a fifty-two week low of $263.30 and a fifty-two week high of $380.76. The firm has a fifty day moving average price of $302.08 and a two-hundred day moving average price of $310.65. The company has a current ratio of 6.82, a quick ratio of 6.15 and a debt-to-equity ratio of 0.41.
Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, October 24th. The life sciences company reported $1.93 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.40 by $0.53. The firm had revenue of $907.00 million for the quarter, compared to analyst estimates of $872.65 million. Illumina had a return on equity of 22.05% and a net margin of 28.14%. The business’s quarterly revenue was up 6.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.52 EPS. As a group, research analysts predict that Illumina, Inc. will post 6.44 EPS for the current year.
ILMN has been the topic of several recent analyst reports. ValuEngine cut Illumina from a “buy” rating to a “hold” rating in a report on Friday, October 25th. Cowen set a $320.00 target price on Illumina and gave the company a “buy” rating in a research report on Friday, October 25th. Canaccord Genuity lifted their target price on Illumina from $300.00 to $310.00 and gave the company a “hold” rating in a research report on Friday, October 25th. Piper Jaffray Companies dropped their target price on Illumina from $348.00 to $341.00 and set an “overweight” rating on the stock in a research report on Friday, October 25th. Finally, BidaskClub lowered Illumina from a “buy” rating to a “hold” rating in a research report on Saturday. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and ten have assigned a buy rating to the stock. Illumina presently has an average rating of “Buy” and an average price target of $333.38.
In related news, SVP Mostafa Ronaghi sold 4,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $310.93, for a total transaction of $1,243,720.00. Following the transaction, the senior vice president now directly owns 80,585 shares of the company’s stock, valued at approximately $25,056,294.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jay T. Flatley sold 3,300 shares of the business’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $283.41, for a total value of $935,253.00. Following the transaction, the director now directly owns 262,733 shares in the company, valued at $74,461,159.53. The disclosure for this sale can be found here. Insiders have sold a total of 32,638 shares of company stock worth $9,580,415 over the last three months. 0.38% of the stock is owned by insiders.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Featured Story: How to track put option volume
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.